Matinas Biopharma Holdings Inc
ASE:MTNB
Other Pre-Announcement
Matinas Biopharma Provides Business Update And 2023 Strategic Outlook
Published: 01/30/2023 22:10 GMT
Matinas Biopharma Holdings Inc (MTNB) - Matinas Biopharma Provides Business Update and 2023 Strategic Outlook.
Matinas Biopharma Holdings Inc - Ended 2022 With Approximately $28.8 Million, Sufficient to Fund Planned Operations Into Q2 2024.
Matinas Biopharma Holdings - Prioritization on Building External Partnerships and an Internal Pipeline Centered on Gene Therapies and Nucleic Acids.
Matinas Biopharma Holdings Inc - Collaborations With Biontech and National Resilience Expected to Generate Initial in Vivo Data in 1h 2023.
Matinas- Seeking Barda Financial Support & FDA Feedback on Phase 3 Study in Invasive Fungal Infections of Mat2203 Prior to Commencing Phase 3 Program.
Matinas Biopharma Holdings Inc - Ended 2022 With Approximately $28.8 Million, Sufficient to Fund Planned Operations Into Q2 2024.
Matinas Biopharma Holdings - Prioritization on Building External Partnerships and an Internal Pipeline Centered on Gene Therapies and Nucleic Acids.
Matinas Biopharma Holdings Inc - Collaborations With Biontech and National Resilience Expected to Generate Initial in Vivo Data in 1h 2023.
Matinas- Seeking Barda Financial Support & FDA Feedback on Phase 3 Study in Invasive Fungal Infections of Mat2203 Prior to Commencing Phase 3 Program.